Latest News

AbbVie’s stock gains on fourth-quarter earnings as it reports better-than-expected sales of Humira

0

An earlier version of this report referred to Humana in the headline, not Humira. It has been corrected.

Shares of AbbVie Inc. ABBV, +0.08% gained 1.4% in premarket trading on Wednesday after the company beat earnings expectations and generated more sales than expected of its top-selling rheumatoid arthritis drug, Humira. AbbVie had earnings of $4.0 billion, or $2.26 per share, in the fourth quarter of 2021, compared with $36.0 million, or 1 cent per share, in the same quarter a year ago. Adjusted earnings per share were $3.31, against a FactSet consensus of $3.28. The company reported revenue of $14.8 billion in the final quarter of 2021, compared with the $13.8 billion it reported in the fourth quarter of last year. The FactSet consensus was $14.9 billion. Humira remains the company’s top-selling drug, bringing in $5.3 billion in revenue in the fourth quarter of 2021. That’s about one-third of AbbVie’s total revenue for the quarter. The FactSet consensus for Humira revenue was $5.4 billion. AbbVie said it now expects to have adjusted EPS of $14.00 to $14.20 in 2022. The company’s stock is up 32.4% over the past year, while the broader S&P 500 SPX, +0.69% has gained 20.4%.

Members Of Congress Load Up On Their Favorite 10 Stocks

Previous article

Alphabet Stock Split Could Permit Tech Giant to Join Dow Industrials

Next article

You may also like

Comments

Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News